Additional Details
-
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
Stanford University School of MedicinePalo Alto CA. 94304 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
University of Nebraska Medical CenterOmaha NE. 68198-3025 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
University of ColoradoAurora CO. 80045 -
Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors
Harvard Medical School - Brigham and Women's HospitalBoston MA. 02115 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of AlabamaBirmingham AL. 35294 -
Myositis Interstitial Lung Disease Nintedanib Trial
Mayo Clinic ArizonaScottsdale AZ. 85259 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of South FloridaTampa FL. 33612 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of PittsburghPittsburgh PA. 15216 -
Myositis Interstitial Lung Disease Nintedanib Trial
Johns Hopkins UniversityBaltimore MD. 21224 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of Utah Health Sciences CenterSalt Lake City UT. 84112 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of Kansas Medical CenterKansas City KS. 66160 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of PennsylvaniaPhiladelphia PA. 19104 -
Myositis Interstitial Lung Disease Nintedanib Trial
National Jewish HealthDenver CO. 80206 -
Myositis Interstitial Lung Disease Nintedanib Trial
University of ChicagoChicago IL. 60637 -
Myositis Interstitial Lung Disease Nintedanib Trial
Massachusetts General HospitalBoston MA. 02114 -
Myositis Interstitial Lung Disease Nintedanib Trial
Columbia University Irving Medical CenterNew York NY. 10032 -
Myositis Interstitial Lung Disease Nintedanib Trial
UCLA Medical CenterLos Angeles CA. 90095 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
UCLA Health Westwood Medical PlazaWestwood CA. 90095 -
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Piedmont Pulmonary and Sleep Medicine BuckheadAtlanta GA. 30309-1740